Finsbury's Last Stand
Executive Summary
One of the most innovative and creative orthopedic implant designers, the UK's Finsbury's Orthopedics never quite built the sales and distribution capability to enable it to capture the full value of its designs. The company's recent sale to DePuy underscores how much the orthopedics industry has changed since its earliest days.
You may also be interested in...
Biomet Roars Back
Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover Covidien's acquisition of ev3, J&J's moves in the endovascular market, DePuy's launch of new products in hip revision, and FDA regulation of consumer genomics.
Biomet Roars Back
Five years ago, Biomet was in turmoil, as the board announced the company was for sale and the company's long-time CEO stepped down. The eventual buyers: a group of leading private equity firms. Biomet still faced a number of internal challenges, including fixing a spine and trauma business that was performing poorly. Critical to Biomet's turnaround was re-establishing the culture of stability that had long characterized the company. At the same time, it now has a new, more aggressive focus on capturing market share commensurate with its role as a top orthopedics company.